Andrew Lepisto, PhD, did his undergraduate training at Washington and Jefferson College, obtaining his BA in Molecular Biology in 1999. He then entered the University of Pittsburgh School of Medicine graduate program where he did his PhD work in the laboratory of Robert L. Hendricks, studying the evolution of the immune response in the corneas of mice following herpes simplex infection. The focus of his work was on the activation of helper T cells; more specifically, he examined the role of T cell costimulatory interactions, including OX40/OX40L in the immunopathological response in the eye leading to blindness. Following completion of his PhD in 2005, he then spent 2 years as a postdoctoral fellow in the laboratory of Dr. Olivera Finn in the Department of Immunology at the University of Pittsburgh, studying pre-clinical mouse models of pancreatic cancer, as well as analyzing samples from a Phase I clinical trial in pancreatic cancer. During his postdoctoral fellowship, Andy was a visiting adjunct professor at Washington and Jefferson College where he taught immunology as well as a visiting assistant professor at Duquesne University where he team-taught immunology to undergraduate students and pharmacy students. In 2007, Andy took a position with Bristol-Myers Squibb as a medical science liaison (MSL) and has subsequently been promoted to senior MSL and now executive MSL.